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Abstract
The ability to perform whole-exome and, increasingly, whole-genome sequencing on
large numbers of individuals has led to increased eﬀorts to identify rare genetic vari-
ants that aﬀect the risk of both common and rare diseases. In such applications, it is
important to identify families that are segregating the rare variants of interest. For rare
diseases or rare familial forms of common diseases, pedigrees with multiple aﬀected
members are clearly harbouring risk variants. For more common diseases, however, it
may be unclear whether a family with a few aﬀected members is segregating a familial
disease, is the result of multiple sporadic cases, or is a mixture of familial cases and
phenocopies. We provide calculations for the probability that a family is harbouring
familial disease, presented in general terms that admit working guidelines for select-
ing families for current sequencing studies. Using examples motivated by our own
studies of thyroid cancer and published studies of colorectal cancer, we show that for
common diseases, families with exactly two aﬀected ﬁrst-degree relatives have only
a moderate probability of segregating familial disease, but this probability is higher
for families with three or more aﬀected relatives, and those families should therefore
be prioritised in sequencing studies.
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1 INTRODUCTION
In recent years, the ability to perform whole-exome and,
increasingly, whole-genome sequencing on large numbers of
individuals has led to increased eﬀorts to identify rare genetic
variants that aﬀect the risk of disease (Goodwin, Mcpherson,
& Mccombie, 2016). In the case of rare Mendelian diseases,
sequencing has obviated the need for linkage and ﬁne map-
ping analyses in pedigrees, allowing more direct identiﬁcation
of causal variants. For common diseases, familial forms may
exist that can be regarded as Mendelian disorders, or there
may be rare variants with reduced penetrance that account for
some familial aggregation and explain some of the missing
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heritability not identiﬁed by genome-wide association studies
of common variation.
In each of these applications, it is important to identify fam-
ilies that are segregating the rare variants of interest. For rare
diseases or familial forms, pedigrees with multiple aﬀected
members are clearly harbouring risk variants. For example,
a study of Waldenström macroglobulinemia identiﬁed two
novel candidate genes by exome sequencing three aﬀected
and one unaﬀected members of one pedigree, together with
50 unrelated cases with a family history and 196 cases with-
out (Roccaro et al., 2016). Similarly, a study of familial bipo-
lar disorder identiﬁed a number of candidate genes by exome
sequencing eight families, originally ascertained for linkage
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studies, each with at least four aﬀected members (Goes et al.,
2016). Similar strategies have been successful for other rare
phenotypes (Preuss et al., 2016; Braun et al., 2016).
For more common diseases, however, it may be unclear
whether a family with a few aﬀected members is segregat-
ing a single variant with incomplete penetrance, is the result
of multiple sporadic (or polygenic) cases, or includes a mix-
ture of familial cases and phenocopies. For example, a recent
study of colorectal cancer performed exome sequencing in
1006 early-onset cases with at least one aﬀected ﬁrst-degree
relative but could only ascribe 16% of familial disease to
highly penetrant rare mutations (Chubb et al., 2016). On the
other hand, in another study of colorectal cancer in which
cases were selected to have at least three aﬀected relatives, 22
of the 29 families showed evidence for segregating variants
(Esteban-Jurado et al., 2015).
Our own study aimed to ﬁnd rare variants causing famil-
ial nonmedullary thyroid cancer, a rare form of diﬀerentiated
thyroid cancer, using a series of families, the majority hav-
ing two or three aﬀected individuals (Weeks et al., 2016).
With an estimated lifetime risk less than 0.02 (Threlfall &
Thompson, 2015), thyroid cancer is not common but is not
as rare as many Mendelian diseases (which typically have
a prevalence below 1 in 2000). However, familial disease
is estimated to be present in only about 5% of thyroid can-
cer cases (Khan, Smellie, Nutting, Harrington, & Newbold,
2010). Previously it has been of interest to identify famil-
ial cases in order to study clinical characteristics of the dis-
ease such as its increased local invasiveness. Calculations by
Charkes (2006) suggested that only 60.6% of families with
two or more aﬀected individuals are harbouring the familial
form of this disease, but when there are three or more aﬀected
members, almost all families have the familial form. Such cal-
culations are also relevant for informing the eﬃcient selection
of families for sequencing studies. Of course, formal segre-
gation analysis may be applied to any given family to deter-
mine the likelihood of it segregating a rare variant, but such
calculations can be challenging in a clinical environment, in
which it may be more useful to have practical guidelines for
identifying families worth following up more closely. Our aim
here is to provide calculations for the probability that a family
is harbouring a familial form of disease and to present these
calculations in general terms that admit working guidelines
for selecting families for the current generation of sequenc-
ing studies. Our approach is similar to that of Charkes (2006),
but we consider ascertainment more explicitly and correct an
error in a probability calculation, leading to quantitatively dif-
ferent results from those previously reported.
2 METHODS
Let us distinguish between families that harbour a presumed
disease mutation (“F-families”) or do not (“R-families”). Let
𝑝𝑅 be the risk of sporadic disease; if the familial form is rare,
then 𝑝𝑅 is approximately the population risk. For the present
purposes, we include polygenic eﬀects in the sporadic risk.
Also let 𝑝𝐹 be the risk of familial disease for individuals in
an F-family, excluding the proband. This quantity depends on
both the penetrance of the presumed mutation and the rela-
tionship of individuals to the proband. Here, we will only
consider the ﬁrst-degree relatives of the proband, so, for exam-
ple, 𝑝𝐹 can be taken as 0.5 for a fully penetrant dominant
mutation. For more general pedigrees, 𝑝𝐹 could be understood
as an average over the individuals considered; though less pre-
cise than a proper segregation analysis, we shall see that this
simple parameterisation allows ready calculation of practical
guidelines for identifying F-families.
We want the probability that a family of size kwithm cases,
excluding the proband, is an F-family. Assuming that family
size is independent of whether a family is an F- or R-family,
Pr(F |𝑚; 𝑘) = Pr(𝑚 |F; 𝑘) Pr(F)
Pr(𝑚 |F; 𝑘) Pr(F) + Pr(𝑚 |R; 𝑘) Pr(R) (1)
For F-families, the probability of observing m cases is the
probability of observing 𝑚𝐹 familial and 𝑚 − 𝑚𝐹 sporadic
cases, summed over 𝑚𝐹 = 0,… , 𝑚. The probability of 𝑚𝐹
familial cases in an F-family of size k is given by the bino-
mial distribution as(
𝑘
𝑚𝐹
)
𝑝
𝑚𝐹
𝐹
(1 − 𝑝𝐹 )𝑘−𝑚𝐹 ,
and the probability of 𝑚 − 𝑚𝐹 sporadic cases among the
remaining 𝑘 − 𝑚𝐹 family members is(
𝑘 − 𝑚𝐹
𝑚 − 𝑚𝐹
)
𝑝
𝑚−𝑚𝐹
𝑅
(1 − 𝑝𝑅)𝑘−𝑚.
Therefore,
Pr(𝑚 |F; 𝑘) = 𝑚∑
𝑚𝐹=0
(
𝑘
𝑚𝐹
)
𝑝
𝑚𝐹
𝐹
(1 − 𝑝𝐹 )𝑘−𝑚𝐹
×
(
𝑘 − 𝑚𝐹
𝑚 − 𝑚𝐹
)
𝑝
𝑚−𝑚𝐹
𝑅
(1 − 𝑝𝑅)𝑘−𝑚 (2)
(This formula corrects an error in the power of (1 − 𝑝𝑅) in
the Appendix of Charkes [2006]).
For R-families, only sporadic cases can be observed, and
so
Pr(𝑚 |R; 𝑘) = (𝑘
𝑚
)
𝑝𝑚
𝑅
(1 − 𝑝𝑅)𝑘−𝑚 (3)
To calculate Pr(F |𝑚; 𝑘) then, we require values for 𝑝𝐹 , 𝑝𝑅,
and the proportion of F-families Pr(F). These can often be
estimated from epidemiological data, as we show below.
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3 RESULTS
We revisit the example of thyroid cancer presented by Charkes
(2006). The lifetime risk was estimated from cancer reg-
istry data as 𝑝𝑅 = 0.0031. The risk of familial disease in
F-families was calculated from families with at least three
aﬀected ﬁrst-degree relatives, for which it will be shown that
the vast majority contain three familial cases. Charkes (2006,
Table 2) reported 23 cases among 72 subjects in 7 families,
from which a naïve estimate of 𝑝𝐹 was taken as 23/72= 0.319.
As noted however, this estimate does not account for ascer-
tainment. To obtain a more accurate estimate, accounting for
selection of families with at least two aﬀected ﬁrst-degree rel-
atives of the proband, we deﬁne a likelihood for 𝑝𝐹 as the
binomial probability of m cases in a family of size k, exclud-
ing the proband, divided by the cumulative probability of at
least two such cases. Over the seven families tabulated by
Charkes, numerical maximisation of this likelihood gives our
ascertainment-corrected estimate as 𝑝𝐹 = 0.0981.
To estimate the proportion of F-families Pr(F), we use the
fact that of 8214 aﬀected families tabulated by Charkes (2006,
Table 1A), 260 had at least two cases. In R-families, the prob-
ability of at least one additional case to the proband is
𝑘∑
𝑚=1
(
𝑘
𝑚
)
𝑝𝑚
𝑅
(1 − 𝑝𝑅)𝑘−𝑚
Assuming an average number of 𝑘 = 8 ﬁrst-degree rel-
atives of the proband and using 𝑝𝑅 = 0.0031 as estimated
from cancer registry data, this probability is 0.0245. In F-
families, Equation (2) may be summed in the same way, using
𝑝𝐹 = 0.0981 as estimated above, to obtain the corresponding
probability as 0.573. The total proportion of families with one
additional case is then
260
8214
= 0.573 Pr(F) + 0.0245 Pr(R)
with the solution Pr(F) = 0.013, Pr(R) = 0.987. For a family
with eight ﬁrst-degree relatives of the proband, of which just
one is aﬀected, we use Equations (1) and (2) to obtain
Pr(F |𝑚 = 1; 𝑘 = 8) = 0.172
Thus, under these parameters, there is only a roughly 1 in
6 chance that such a family is segregating a familial form of
disease. This is somewhat lower than the ﬁgure of 0.323 previ-
ously calculated for the same data (Charkes, 2006), although
both results suggest that an F-family is unlikely.
Figure 1 shows the probability that a family with exactly
one additional case is an F-family, for diﬀerent family sizes.
For larger families, the probability of familial disease is lower,
because if it were present we should expect a higher number
of cases. Conversely, for smaller families, the higher propor-
tion of cases is more consistent with familial disease. There-
fore, the probability of familial disease depends critically on
F IGURE 1 Probability of an F-family for diﬀerentiated thyroid
cancer. Family size, total size of family including proband and ﬁrst-
degree relatives with known aﬀection status (= k+ 1). Circles and solid
line, proband has exactly m = 1 aﬀected ﬁrst relative. Triangles and
dashed line, proband has two aﬀected ﬁrst degree relatives
the number of family members whose disease status can be
ascertained.
For families with two additional cases, the probability of an
F-family is 0.882 for 𝑘 = 8 , and over 90% for smaller families
(Figure 1). For families with three additional cases, there is
over 99% probability of an F-family for all family sizes up
to 𝑘 = 8. Therefore, as claimed above, families with at least
three cases may be safely assumed to be F-families. Among
such families, we can calculate the chance that all aﬀected
relatives have the familial form of disease. This is(
𝑘
𝑚
)
𝑝𝑚
𝐹
(1 − 𝑝𝐹 )
𝑘−𝑚(1 − 𝑝𝑅)
𝑘−𝑚
𝑚∑
𝑚𝐹=0
(
𝑘
𝑚𝐹
)
𝑝
𝑚𝐹
𝐹
(1 − 𝑝𝐹 )
𝑘−𝑚𝐹
(
𝑘 − 𝑚𝐹
𝑚 − 𝑚𝐹
)
𝑝
𝑚−𝑚𝐹
𝑅
(1 − 𝑝𝑅)
𝑘−𝑚
,
in which the numerator is the probability that all m additional
cases have familial disease, with the remaining k-m relatives
unaﬀected, and the denominator is the probability of m cases
in an F-family as given by Equation (2).
The probability that all aﬀected relatives have familial dis-
ease is 0.945 when m = 2 and remains high at 0.799 even
when all eight relatives are aﬀected. In the example of thyroid
cancer, then, a general guideline might be that families with
at least two aﬀected ﬁrst-degree relatives of the proband are
highly likely to be segregating familial nonmedullary thyroid
cancer. In such families, it is highly likely that all cases have
the familial form.
For comparison, we repeat these calculations for colorec-
tal cancer, a more common condition. Recall that Chubb
et al. (2016) sequenced early-onset cases with at least one
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F IGURE 2 Probability of an F-family for colorectal cancer. Fam-
ily size, total size of family including proband and ﬁrst-degree relatives
with known aﬀection status (= k+ 1). Circles and solid line, proband has
exactly m = 1 aﬀected ﬁrst relative. Triangles and dashed line, proband
has two aﬀected ﬁrst-degree relatives. Crosses and dotted line, proband
has three aﬀected ﬁrst-degree relatives
aﬀected ﬁrst-degree relative. We will calculate the probability
that these pedigrees have familial disease. A rough estimate
of 𝑝𝐹 can be obtained from another recent study of pedi-
grees with three or more aﬀected relatives, two or more
consecutive aﬀected generations, at least one early-onset
case, and segregation consistent with autosomal dominance
(Esteban-Jurado et al., 2015). In each of the 29 pedigrees
described, we selected an index case and its ﬁrst-degree rel-
atives such that the number of aﬀected relatives was max-
imised. This led to a total of 68 aﬀected relatives out of 241,
and an ascertainment-naïve estimate of 𝑝𝐹 = 0.282. Since the
ascertainment was more strict than in Chubb et al., we atten-
uated this to 𝑝𝐹 = 0.2 to allow for selection of less clearly
familial pedigrees. Finally, assume the lifetime risk of 𝑝𝑅 =
0.05 (Esteban-Jurado et al., 2015).
Chubb et al. (2016) identiﬁed penetrant rare mutations in
16% of families with at least one aﬀected ﬁrst-degree relative.
Allowing for incomplete power in that study, suppose
Pr(F |𝑚 ≥ 1) = 0.2. From Bayes’ theorem,
Pr(F |𝑚 ≥ 1) = ∑𝑘𝑚=1 Pr(𝑚 |F) Pr(F)∑𝑘
𝑚=1 Pr(𝑚 |F) Pr(F) + Pr(𝑚 |R) Pr(R) = 0.2
Using Equations (2) and (3) to evaluate the sums assuming
𝑘 = 8, we solve to obtain Pr(F) = 0.0865. Equation (1) then
gives Pr(F |𝑚 = 1; 𝑘 = 8) = 0.0870.
Thus, the chance of such a family having familial disease
is lower than for thyroid cancer, owing to the higher sporadic
risk of disease. Figure 2 shows the probability of an F-family
for diﬀerent family sizes and numbers of aﬀected relatives.
For two aﬀected relatives, the probability of an F-family is
still only 36.4%, but increases to over 77% for three or more
relatives.
For 𝑘 = 8 relatives, the probabilities that all cases in an
F-family are familial are lower than for our example of
diﬀerentiated thyroid cancer, ranging from 0.694 for 𝑚 = 2
to 0.233 for 𝑚 = 8. However, allowing for one sporadic rel-
ative per family gives higher probabilities of the remainder
being familial: 0.972 for 𝑚 = 2 to 0.605 for 𝑚 = 8. Overall
then, similar conclusions apply for colorectal cancer as for
thyroid cancer: probands with only one aﬀected relative have
only moderate probability of being an F-family, but those with
two or more aﬀected relatives have high probability of being
an F-family, and nearly all of those cases are familial. Thus, for
both of these diseases, a good rule for identifying rare famil-
ial mutations would be to sequence families with at least two
aﬀected ﬁrst-degree relatives of the proband.
4 DISCUSSION
Our approach diﬀers from that of Charkes (2006) in sev-
eral ways. Rather than considering all possible conﬁgura-
tions of cases in a family, we have omitted the proband from
the calculations and considered only its relatives. We believe
the latter to be more appropriate because within any pedi-
gree the set of relevant (e.g., ﬁrst-degree) relatives depends
on the identity of the proband, and thus the binomial trial
design itself is conditional on the proband. Formula (2) cor-
rects an error in the power of (1 − 𝑝𝑅) in the Appendix of
Charkes (2006). Finally, we have more explicitly allowed for
ascertainment in estimating 𝑝𝐹 . However, the conclusions
remain very similar under our improved calculations. Note
that we assumed that family size is independent of famil-
ial disease, which may be untrue in reality. Furthermore,
the distinction between familial and sporadic disease is less
clear when searching for low-penetrance variants. To esti-
mate the proportion of F-families, epidemiological data on
multiply aﬀected pedigrees can be used, but they may not be
representative of the smaller pedigrees arising from reduced
penetrance. Nevertheless, our results suggest that for both
rare and common disease, probands should have at least two
aﬀected ﬁrst-degree relatives for there to be a high chance that
the family is segregating a penetrant rare variant. A spread-
sheet implementing our calculations is provided as Support-
ing Information and a more detailed R package is available
from https://github.com/DudbridgeLab/probFamilial/.
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